Blogs

The European Union's bid to update its clinical trials rules, "is particularly important for better competitiveness at global level, by encouraging research and innovation, maintaining a strong pharmaceutical industry and more clinical trials in Europe, and seeking better access to drugs for EU citizens."

You know those moments when you come across a really exciting idea, and you say to yourself, "why didn't I think of that?"

Recently, the National Health Service (NHS) in the UK announced that there was an increase of NHS patients participating in clinical research.

A recent paper published in PLOS ONE addresses research institutions? willingness ?or lack thereof?to defer to central institutional review boards for multicenter clinical trials.

This is certainly a question that stimulates a great deal of debate amongst industry professionals, even those working in Pharma companies that explicitly request all CRAs working on their projects have at least 2 years? prior experience

With the increasing challenges associated with bringing a medical product to market, and skyrocketing R&D costs, there has been a shift in biopharmaceutical commercialization and clinical trial strategies in order to minimize risk and maximize success.

With ISR?s newest market research report (?Risk-based Monitoring: Industry Guidance on Adoption, Use, and Outsourcing?) Mr. Schafer is back to draw comparisons and share data from their latest survey.

The Supreme Court decision blocking patents on naturally-occurring genes has generated predictions of doom for biotech innovation, along with expectations of more healthy competition in discovering new treatments and diagnostics.

Women should be represented more in studies and greater attention paid to their general health issues.

This year, CBI will be co-locating their Risk-Based Monitoring in Clinical Studies conference and Clinical Patient Engagement Summit this October 24-25, 2013 in Philadelphia.

Debate rages on, European Parliament set to decide on new clinical trial rules in late October.

The clinical trial debate in the European Parliament is bogged down by rival schools of thought.